267. CURRENT STATUS OF COMPREHENSIVE GENOME PROFILING FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA

Abstract

Abstract Esophageal squamous cell carcinoma (ESCC) is the dominant histological subtype of esophageal cancer in Japan. However, there are few effective drugs for advanced ESCC patients (pts), and the prognosis of advanced ESCC pts remains poor. In 2019, comprehensive genome profiling (CGP) tests were approved for patients with advanced solid cancers who were refractory or intolerant to standard treatments. However, there were little data on CGP tests for advanced ESCC patients. The subjects were advanced ESCC patients received CGP tests between June 2019 and February 2022 and expected to be refractory or intolerant to standard treatments. This study evaluated characteristics of advanced ESCC patients who received CGP tests and the clinical utility of CGP tests to receive investigational new drugs. Characteristics of 12 patients were follows; median age:61(range: 48–72), male/female:10(83.3%)/2(16.7%)pts, performance status 0/1/2:2(16.7%)/9(75.0%)/1(8.3%)pts, treatment line 2/3/4:3(25.0%)/8(66.7%)/1(8.3%)pts CGP tests FoundationOne CDx/OncoGuideTM NCC Oncopanel System:8(66.7%)/4(33.3%)pts. All pts(100%) and 7pts(58.3%), 5pts(41.7%), 4pts(33.3%), 2pts(16.7%) showed TP53 mutations and CDKN2A/B loss, FGF amplification, NFE2L2 mutations, TMB-high. Seven pts(58.3%) were candidates for investigational new drugs based on CGP, 1 pt(8.3%) received investigational treatment based on CGP (ERBB2 amplification), 1 pt(8.3%) received investigational treatment not based on CGP test. 5pts(41.7%) were ineligible to trials according to deteriorated general condition or prior treatments. In 5pts(41.7%) without druggable gene alteration based on CGP tests, 2pts(16.7%) received investigational treatments not based on CGP. This study clarified the current status of CGP tests for advanced ESCC patients in our hospital. Due to the small population, further investigation was needed to evaluate the utility of CGP for ESCC pts.